FullText URL fulltext.pdf
Author Sekito, Takanori| Wada, Koichiro| Ishii, Ayano| Iwata, Takehiro| Matsubara, Takehiro| Tomida, Shuta| Watanabe, Masami| Araki, Motoo| Sadahira, Takuya|
Keywords cystitis vagina microbiota Lactobacillus urinary tract infection
Published Date 2023-05-18
Publication Title Frontiers in Microbiology
Volume volume14
Publisher Frontiers Media
Start Page 1187479
ISSN 1664-302X
Content Type Journal Article
language English
OAI-PMH Set 岡山大学
Copyright Holders © 2023 Sekito, Wada, Ishii, Iwata, Matsubara, Tomida, Watanabe, Araki and Sadahira.
File Version publisher
PubMed ID 37275169
DOI 10.3389/fmicb.2023.1187479
Web of Science KeyUT 000998008400001
Related Url isVersionOf https://doi.org/10.3389/fmicb.2023.1187479
Author Ishii, Ayano|
Published Date 2001-04-28
Publication Title 岡山医学会雑誌
Volume volume113
Issue issue1
Content Type Journal Article
Author Ishii, Ayano|
Published Date 2001-03-25
Publication Title
Content Type Thesis or Dissertation
JaLCDOI 10.18926/AMO/62820
FullText URL 75_6_763.pdf
Author Iwata, Takehiro| Sadahira, Takuya| Maruyama, Yuki| Sekito, Takanori| Yoshinaga, Kasumi| Watari, Shogo| Nagao, Kentaro| Kawada, Tatsushi| Tominaga, Yusuke| Nishimura, Shingo| Takamoto, Atsushi| Sako, Tomoko| Edamura, Kohei| Kobayashi, Yasuyuki| Araki, Motoo| Ishii, Ayano| Watanabe, Masami| Watanabe, Toyohiko| Nasu, Yasutomo| Wada, Koichiro|
Abstract The aim of this ongoing trial is to evaluate the clinical efficacy and safety of sitafloxacin (STFX) 200 mg once daily (QD) for 7 days in patients with refractory genitourinary tract infections, which include recurrent or complicated cystitis, complicated pyelonephritis, bacterial prostatitis, and epididymitis. The primary endpoint is the microbiological efficacy at 5-9 days after the last administration of STFX. Recruitment began in February 2021, and the target total sample size is 92 participants.
Keywords genitourinary tract infections fluoroquinolone resistance extended-spectrum beta-lactamase
Amo Type Clinical Study Protocol
Publication Title Acta Medica Okayama
Published Date 2021-12
Volume volume75
Issue issue6
Publisher Okayama University Medical School
Start Page 763
End Page 766
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language English
Copyright Holders Copyright Ⓒ 2021 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 34955548
Web of Science KeyUT 000735319800006
NAID 120007180272
JaLCDOI 10.18926/AMO/54508
FullText URL 70_4_299.pdf
Author Wada, Koichiro| Uehara, Shinya| Ishii, Ayano| Sadahira, Takuya| Yamamoto, Masumi| Mitsuhata, Ritsuko| Takamoto , Atsushi| Araki, Motoo| Kobayashi, Yasuyuki| Watanabe, Masami| Watanabe, Toyohiko| Hotta, Katsuyuki| Nasu, Yasutomo|
Abstract Urinary tract infections (UTIs) are the most common bacterial infections in women, and many patients experience frequent recurrence. The aim of this report is to introduce an on-going prospective phase II clinical trial performed to evaluate the preventive effectiveness of Lactobacillus vaginal suppositories for prevention of recurrent cystitis. Patients enrolled in this study are administered vaginal suppositories containing the GAI 98322 strain of Lactobacillus crispatus every 2 days or 3 times a week for one year. The primary endpoint is recurrence of cystitis and the secondary endpoints are adverse events. Recruitment began in December 2013 and target sample size is 20 participants.
Keywords probiotics lactobacilli Lactobacillus crispatus urinary tract infection vaginal suppository
Amo Type Clinical Study Protocols
Publication Title Acta Medica Okayama
Published Date 2016-08
Volume volume70
Issue issue4
Publisher Okayama University Medical School
Start Page 299
End Page 302
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language English
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 27549677
Web of Science KeyUT 000384748600012
JaLCDOI 10.18926/AMO/52405
FullText URL 68_2_89.pdf
Author Sako, Shinichi| Kariyama, Reiko| Mitsuhata, Ritsuko| Yamamoto, Masumi| Wada, Koichiro| Ishii, Ayano| Uehara, Shinya| Kokeguchi, Susumu| Kusano, Nobuchika| Kumon, Hiromi|
Abstract We conducted a study on molecular epidemiology and clinical implications of metallo-β-lactamase (MBL)-producing Pseudomonas aeruginosa isolated from urine. Over a 10-year period from 2001 through 2010, a total of 92 MBL-producing P. aeruginosa urine isolates were collected from patients (one isolate per patient) who were admitted to 5 hospitals in Okayama Prefecture, Japan. When cross-infection was suspected in the hospital, pulsed-field gel electrophoresis was performed. In the resulting dendrogram of 79 MBL-producing P. aeruginosa urine isolates, no identical isolates and 7 pairs of isolates with ≥80% similarity were found. The biofilm-forming capabilities of 92 MBL-producing P. aeruginosa urine isolates were significantly greater than those of 92 non-MBL-producing urine isolates in a medium of modified artificial urine. The imipenem resistance transferred in 16 of 18 isolates tested, and these frequencies were in the range of 10-3 to 10-9. All of 18 isolates tested belonged to internationally spread sequence type 235 and had 3 gene cassettes of antimicrobial resistance genes in the class 1 integron. The strong biofilm-forming capabilities of MBL-producing P. aeruginosa urine isolates could be seriously implicated in nosocomial infections. To prevent spread of the organism and transferable genes, effective strategies to inhibit biofilm formation in medical settings are needed.
Keywords Pseudomonas aeruginosa metallo-β-lactamase molecular epidemiology biofilm urinary tract infection
Amo Type Original Article
Publication Title Acta Medica Okayama
Published Date 2014-04
Volume volume68
Issue issue2
Publisher Okayama University Medical School
Start Page 89
End Page 99
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language English
Copyright Holders CopyrightⒸ 2014 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 24743784
Web of Science KeyUT 000334652700004
Related Url http://ousar.lib.okayama-u.ac.jp/metadata/52504
JaLCDOI 10.18926/AMO/48078
FullText URL 66_1_23.pdf
Author Watanabe, Toyohiko| Inoue, Miyabi| Ishii, Ayano| Yamato, Toyoko| Yamamoto, Masumi| Sasaki, Katsumi| Kobayashi, Yasuyuki| Araki, Motoo| Uehara, Shinya| Saika, Takashi| Kumon, Hiromi|
Abstract Polypropylene mesh implants for the correction of pelvic organ prolapse (POP) are now available in Japan. We developed an innovative approach for correcting POP by placing polypropylene mesh transvaginally with laparoscopic assistance. From June 2007 through March 2010, sixteen consecutive patients with symptomatic stage 2 or 3 pelvic organ prolapse underwent the laparoscopic-assisted tension-free vaginal mesh procedure at Okayama University Hospital. All patients were evaluated before and at 1, 3, 6, and 12 months after surgery. Female sexual function was also evaluated with the Female Sexual Function Index (FSFI). The procedure was performed successfully without significant complications. Fifteen of 16 patients were considered anatomically cured (93.8%) at 12 months postoperatively. One patient with a recurrent stage 3 vaginal vault prolapse required sacral colpopexy six months postoperatively. Total FSFI scores improved significantly from 10.3±1.3 at baseline to 18.0±1.2 at 12 months after surgery. The laparoscopic-assisted trans-vaginal mesh is a safe, effective, and simple procedure for POP repairs. The procedure not only restores anatomic relationships but also improves sexual function.
Keywords tension-free vaginal mesh pelvic organ prolapse laparoscopic female urology sexual function
Amo Type Original Article
Publication Title Acta Medica Okayama
Published Date 2012-02
Volume volume66
Issue issue1
Publisher Okayama University Medical School
Start Page 23
End Page 29
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language English
Copyright Holders CopyrightⒸ 2012 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 22358136
Web of Science KeyUT 000300800700004